Luke Koong, PA
Medical · Houston, TXNPI 1184250524
Payments from drug & device makers
Across 109 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$771
- Amgen$426
- Novo Nordisk$306
- Boehringer Ingelheim$303
- Bayer$231
- Optinose US, Inc.$169
- plus $912 from 16 others
What the payments were for
- Food & beverage$3,09999%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $771 |
| Amgen | 6 | $426 |
| Novo Nordisk | 13 | $306 |
| Boehringer Ingelheim | 16 | $303 |
| Bayer | 10 | $231 |
| Optinose US, Inc. | 3 | $169 |
| Lilly USA, LLC | 10 | $168 |
| GSK | 6 | $122 |
| Sumitomo Pharma America, Inc. | 7 | $116 |
| Otsuka America Pharmaceutical, Inc. | 2 | $116 |
| Pfizer | 3 | $69 |
| Exact Sciences | 3 | $59 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Hologic Sales And Service, LLC | 1 | $35 |
| Phadia US Inc. | 2 | $34 |
| Seqirus USA Inc | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Radius Health, Inc. | 1 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $19 |
| Gilead | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,117 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 93 | $107,832 |
| OzempicSemaglutide | 45 | $97,936 |
| JardianceEmpagliflozin | 71 | $92,896 |
| RybelsusSemaglutide | 33 | $69,107 |
| MounjaroTirzepatide | 19 | $51,703 |
| Xigduo XrDapaglifloz Propaned/Metformin | 30 | $39,813 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $39,260 |
| EliquisApixaban | 39 | $36,874 |
| VascepaIcosapent Ethyl | 41 | $28,585 |
| GemtesaVibegron | 26 | $26,470 |
| KerendiaFinerenone | 23 | $26,356 |
| EntrestoSacubitril/Valsartan | 14 | $26,253 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $23,103 |
| ProliaDenosumab | 12 | $20,671 |
| LinzessLinaclotide | 11 | $18,805 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $306 | $167,04378 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $771 | $130,936120 claims |
| Boehringer IngelheimJardiance | $303 | $92,89671 claims |
| Lilly USA, LLCMounjaro | $168 | $51,70319 claims |
| GSKTrelegy Ellipta | $122 | $39,26031 claims |
| PfizerEliquis | $69 | $36,87439 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $116 | $26,47026 claims |
| BayerKerendia | $231 | $26,35623 claims |
| NovartisEntresto | $21 | $26,25314 claims |
| AmgenProlia | $426 | $20,67112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.
Other medical in Houston
- Olga RodziyenskaHouston$65K
- Kathleen HoganHouston$26K
- Omni McCluneyHouston$18K
- Carl MayberryHouston$18K
- Carley BuddenbaumHouston$16K
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.